InvaGen Pharmaceuticals is recalling 3,222 vials of Decitabine for Injection (50mg per vial), a prescription chemotherapy medication. The recall was initiated because the product failed quality specifications regarding water content and impurities, which can occur as the drug degrades over time. Consumers who have this medication should not use affected vials and should immediately consult their healthcare provider for guidance on alternative treatments.
The presence of excessive moisture or impurities indicates the drug may have degraded, potentially reducing its effectiveness or causing unpredictable side effects during treatment. While no specific injuries were reported, using a degraded chemotherapy drug may compromise the intended medical treatment for the patient.
Healthcare provider consultation and pharmacy refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.